Rezolute Appoints Sunil Karnawat as Chief Commercial Officer for Ersodetug Launch.

Rezolute has appointed Sunil Karnawat as Chief Commercial Officer, effective August 18, 2025. Karnawat brings experience in commercial and biopharmaceuticals leadership, and will spearhead the launch strategy and global market readiness for ersodetug, a treatment for hypoglycemia caused by hyperinsulinism. The appointment comes as the company advances Phase 3 studies for both congenital and tumor hyperinsulinism.

XOMA Royalty Corporation (NASDAQ: XOMA) reported its second quarter and year-to-date financial results for 2025, highlighting recent business achievements and strategic acquisitions. The company continues to expand its diversified portfolio of early- and late-stage assets through disciplined capital deployment and creative financial structures.

Financial Performance:
- Second Quarter 2025: XOMA Royalty received $11.7 million in cash from partners, with $2.6 million from commercial sales and $9.0 million from milestones and fees.
- Year-to-Date 2025: The company received $29.6 million in cash from partners, including $16.0 million from commercial sales and $13.6 million from milestones and fees.
- Income and Revenue: Income and revenue for the three and six months ended June 30, 2025, were $13.1 million and $29.0 million, respectively, compared to $11.1 million and $12.6 million for the corresponding periods of 2024.
- R&D Expenses: R&D expenses for the three and six months ended June 30, 2025, were $0.1 million and $1.4 million, respectively, compared to $1.2 million for each of the corresponding periods of 2024.
- G&A Expenses: G&A expenses for the three and six months ended June 30, 2025, were $7.8 million and $15.9 million, respectively, as compared to $11.0 million and $19.5 million for the corresponding periods of 2024.

Business Highlights:
- Pipeline Advancements: Rezolute completed enrollment in Phase 3 sunRIZE study of ersodetug in patients with congenital hyperinsulinism, resulting in a $5 million milestone payment. The Marketing Authorization Application (MAA) for Day One Biopharmaceuticals and Ipsen’s tovorafenib was accepted for review by the European Marketing Authority (EMA), triggering a $4 million milestone payment.
- Company Acquisitions: XOMA Royalty announced acquisitions of Turnstone Biologics, LAVA Therapeutics, and HilleVax, and acted as structuring agent for XenoTherapeutics’ acquisition of ESSA Pharma. The company also completed the sale of Kinnate pipeline assets.
- Pipeline Partner Updates: Zevra Therapeutics submitted an MAA with EMA seeking marketing approval for arimoclomol as a treatment for Niemann-Pick Type C. Gossamer Bio completed enrollment in the Phase 3 PROSERA Study evaluating seralutinib in pulmonary atrial hypertension patients. Daré Biosciences announced positive interim results from its Phase 3 clinical trial evaluating Ovaprene®.

Appointments and Strategy:
- Rezolute: Sunil Karnawat was appointed Chief Commercial Officer, effective August 18, 2025. Karnawat will spearhead the launch strategy and global market readiness for ersodetug, a treatment for hypoglycemia caused by hyperinsulinism, as the company advances Phase 3 studies for both congenital and tumor hyperinsulinism.

Outlook:
XOMA Royalty Corporation continues to add to its diversified portfolio of early- and late-stage assets through strategic acquisitions and disciplined capital deployment. The company's focus on addressing key unmet patient needs is driving increased royalty receipts, and the potential for data from several key Phase 3 assets over the coming quarters presents a promising outlook.

References:
[1] https://www.biospace.com/press-releases/xoma-royalty-reports-second-quarter-and-year-to-date-2025-financial-results-and-highlights-recent-business-achievements